Examkin

Question

Difficulty: MediumPharmacologic Interventions

A 42-year-old woman is evaluated on the inpatient medical ward for acute-onset agitation, confusion, and severe diaphoresis. She was admitted 2 days ago for a complicated right lower extremity skin abscess, for which she was started on intravenous linezolid. Her past medical history is significant for major depressive disorder, which has been managed with fluoxetine for the past three years. Vital signs show a temperature of 38.9°C (102.0°F), blood pressure of 165/95 mmHg, pulse of 124/min, and respiratory rate of 20/min. Physical examination reveals a flushed, profusely diaphoretic patient who appears restless and continuously shifts in bed. Neurologic examination demonstrates bilateral 4+ patellar reflexes, sustained ankle clonus, and a bilateral resting tremor. Bowel sounds are hyperactive. She is immediately given intravenous normal saline and lorazepam, and her current antimicrobial and antidepressant medications are discontinued. Which of the following is the most appropriate next pharmacologic intervention for this patient's current condition?

  1. A
    Bromocriptine
  2. B
    Dantrolene
  3. C
    Haloperidol
  4. D
    Physostigmine
  5. CyproheptadineAnswer

Answer

The most appropriate next pharmacologic intervention is the administration of cyproheptadine.
This patient is experiencing serotonin syndrome, precipitated by the combination of fluoxetine (a selective serotonin reuptake inhibitor) and linezolid (an antibiotic with reversible monoamine oxidase inhibitor properties). Serotonin syndrome is characterized by the classic triad of autonomic instability (tachycardia, hyperthermia, diaphoresis), altered mental status, and neuromuscular irritability (hyperreflexia, sustained clonus). Initial management includes discontinuing the offending agents and providing supportive care with intravenous fluids and benzodiazepines to control agitation. When symptoms are moderate to severe, the specific serotonin antagonist cyproheptadine is the most appropriate definitive pharmacologic intervention.

Step-by-Step Solution

1
Analyze the patient's medication list and identify potential pharmacokinetic or pharmacodynamic interactions.
The patient is taking fluoxetine (a selective serotonin reuptake inhibitor) and linezolid (an antimicrobial that is also a reversible, nonselective monoamine oxidase inhibitor).
Recognizing the combination of an SSRI and an MAOI is critical to identifying the root cause of the patient's acute decompensation.
2
Correlate the medication history with the clinical presentation (vitals and physical exam findings).
The triad of autonomic instability (tachycardia, hyperthermia, diaphoresis), altered mental status (agitation, confusion), and neuromuscular irritability (hyperreflexia, clonus) confirms the diagnosis of serotonin syndrome.
Hyperreflexia and clonus are the defining characteristics that distinguish serotonin syndrome from other hypermetabolic toxidromes like neuroleptic malignant syndrome.
3
Determine the appropriate sequential management for the diagnosed toxidrome.
Initial steps involve discontinuing the offending agents and providing supportive care (IV fluids, benzodiazepines). Since the question asks for the next specific pharmacologic intervention after supportive measures, a targeted serotonin antagonist is required.
Standard protocols dictate that if symptoms of serotonin syndrome are moderate to severe and refractory to benzodiazepines, targeted pharmacotherapy must be initiated.
4
Select the correct specific antidote from the available options.
Cyproheptadine, a serotonin antagonist, is selected to directly counteract the excess serotonergic activity.
Cyproheptadine directly blocks the 5-HT1A and 5-HT2A receptors responsible for the severe symptoms of the syndrome.

Key Concept

The combination of linezolid and SSRIs can precipitate life-threatening serotonin syndrome. When supportive care with benzodiazepines is insufficient, cyproheptadine (a serotonin antagonist) is the definitive pharmacologic intervention.

Alternative Method

In the most severe, life-threatening cases of serotonin syndrome where hyperthermia exceeds 41.1°C (106.0°F) and the patient is unresponsive to cyproheptadine, immediate intubation, mechanical ventilation, and administration of non-depolarizing neuromuscular blocking agents (e.g., vecuronium) are required to completely halt muscle activity and prevent severe hyperthermia-induced organ damage.
Estimated Time:1m 0s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic